The global precision genomic testing market size was valued at USD 15.57 billion in 2024 and is expected to worth around USD 62.34 billion by 2034, growing at a CAGR of 14.88%.

Get Sample Copy of Report@ https://www.precedenceresearch.com/sample/5732

Key Highlights

• North America dominated the market, securing over 43% of the total share in 2024.

• Asia Pacific is projected to witness the fastest growth, with a CAGR of 20.63% over the forecast period.

• By product and services, the consumables segment led the market with a 46% share in 2024.

• The services segment is anticipated to grow steadily, with a robust CAGR of 15.41% in the coming years.

• By technology, next-generation sequencing (NGS) accounted for a 33% market share in 2024.

• Microarray technology is expanding rapidly, registering a CAGR of 15.80% over the forecast period.

• By application, the oncology segment held the highest share, capturing 33% of the market in 2024.

• The neurological disorders segment is expected to grow at a double-digit CAGR of 16% during the forecast period.

• By end use, hospitals and clinics led the market with a 51% share in 2024.

• The diagnostic laboratories segment is anticipated to expand at the fastest rate over the forecast period.

Role of AI in Precision Genomic Testing Market

1. Accelerated Data Analysis and Interpretation

AI enhances the speed and accuracy of genomic data analysis, enabling rapid identification of genetic mutations and biomarkers. AI-driven algorithms can process vast genomic datasets in a fraction of the time required by traditional methods, significantly reducing turnaround time for precision diagnostics.

2. Improved Accuracy in Genetic Variant Detection

Machine learning models help distinguish between benign and pathogenic genetic variants with higher precision. AI minimizes errors in sequencing data, reducing false positives and false negatives, leading to more reliable diagnostic results.

3. Personalized Treatment Recommendations

AI-powered predictive models analyze patient-specific genetic information to recommend tailored treatment plans. By correlating genetic data with clinical outcomes, AI enhances precision medicine by suggesting the most effective therapies based on an individual’s genetic profile.

4. AI-Powered Drug Discovery and Development

AI facilitates genomic-based drug discovery by identifying potential therapeutic targets. It helps in predicting drug responses, optimizing clinical trials, and accelerating the development of targeted therapies for genetic disorders and cancers.

5. Automation of Genomic Sequencing Workflows

AI streamlines laboratory workflows by automating data pre-processing, variant calling, and report generation. This reduces manual workload, minimizes human errors, and increases efficiency in genomic testing labs.

6. AI in Predictive and Preventive Genomics

By analyzing genomic and lifestyle data, AI predicts the likelihood of developing certain genetic disorders. Early risk assessment allows for proactive medical interventions, lifestyle modifications, and preventive care strategies.

7. Enhancing Population Genomics and Epidemiology

AI processes large-scale genomic data from diverse populations, helping researchers identify genetic predispositions and disease patterns. This aids in public health strategies, personalized healthcare initiatives, and epidemiological studies.

8. AI-Driven Tumor Profiling for Oncology

AI assists in identifying genetic mutations in tumors, leading to more precise cancer classification and treatment selection. AI-powered algorithms improve the accuracy of liquid biopsy analysis, detecting circulating tumor DNA (ctDNA) for early cancer diagnosis.

9. Ethical and Data Security Enhancements

AI ensures robust encryption and security protocols for genomic data storage and sharing. It also helps in maintaining patient privacy by anonymizing sensitive genetic data while facilitating research and collaboration in precision genomics.

10. Integration with Electronic Health Records (EHRs)

AI seamlessly integrates genomic insights with EHRs, allowing clinicians to make informed decisions based on genetic predisposition, treatment history, and real-time health data. This improves patient management and enhances precision healthcare.

Market Overview

The precision genomic testing market is transforming healthcare by enabling targeted therapies and personalized treatment plans. With innovations in genetic sequencing and AI-driven analysis, genomic testing has become an essential tool in identifying hereditary diseases, cancer risk, and rare genetic disorders. The integration of machine learning and big data analytics is making genomic testing more efficient and widely accessible.

Also Read: Hysteroscopy Procedures Market

Market Scope

Market Dynamics

Market Drivers

Key drivers of market growth include rising cases of genetic disorders, increasing funding for genomics research, and improvements in sequencing accuracy. The shift towards precision medicine, where treatments are tailored based on an individual’s genetic profile, is fueling demand for advanced genomic testing solutions. Collaborations between biotech companies and healthcare providers are further accelerating growth.

Market Opportunities

Opportunities lie in expanding applications beyond disease diagnostics, such as nutrigenomics, pharmacogenomics, and ancestry testing. Technological advancements in single-cell sequencing and CRISPR-based diagnostics offer new possibilities. The rise of direct-to-consumer (DTC) genetic testing is also creating a booming market segment.

Market Challenges

Challenges include stringent regulatory approvals, data security concerns, and the high cost of implementing genomic testing infrastructure. Ethical considerations related to genetic privacy and potential misuse of genetic information are also barriers that need to be addressed. Developing standardized protocols for genomic data interpretation remains a key challenge.

Regional Insights

North America continues to lead the market with its advanced healthcare system and research capabilities. Asia Pacific is rapidly catching up due to increased government initiatives and partnerships with international biotech firms. Europe remains a strong player, with a focus on precision medicine and genome-based research programs. Emerging markets in Latin America and the Middle East are also showing growing interest in genomic testing solutions.

Precision Genomic Testing Market Companies

• Danaher
• Merck KGaA
• Revvity, Inc.
• Maravai LifeSciences
• GenScript
• QIAGEN
• PacBio
• Oxford Nanopore Technologies plc.
• Illumina, Inc.
• 10x Genomics, Inc.

Latest Announcement by Market Leaders

• In June 2024, Merck, a leading science and technology company, announced an investment of € 62 million at its Darmstadt headquarters in a new quality control building for its Life Science business. The facility will bring together approximately 135 employees across several departments into one collaborative state-of-the-art space.
• In February 2025, QIAGEN announced the official opening of a new data center in Melbourne, Australia, designed to strengthen its global bioinformatics leadership position in this region of the world. This latest addition reflects QIAGEN’s ongoing commitment to enhance its bioinformatics data infrastructure.

Recent Developments

• In July 2024, Phenomix Sciences partnered with Hello Alpha to introduce personalized genetic testing for obesity, specifically targeting women. Hello Alpha, a virtual primary care platform, seeks to enhance women’s healthcare by offering accessible, affordable, and confidential online medical services.
• In July 2024, Thermo Fisher Scientific Inc. partnered with the National Cancer Institute (NCI), a division of the National Institutes of Health, to advance research on new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). As part of the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial, the collaboration aimed to expedite patient matching for clinical trials.
• In February 2024, Exact Sciences Corp., a provider of cancer screening and diagnostic tests, launched the Riskguard cancer test in the U.S. The Riskguard test offers individualized patient reports that detail gene-specific and familial risks for 10 common cancers.

Segments Covered in the Report

By Product & Service

• Consumables
• Kits
• Reagents
• Equipment
• Services

By Technology

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Microarray Technology
• Sanger Sequencing
• CRISPR/Cas Systems
• Others

By Application

• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Reproductive Health
• Rare Diseases
• Others

By End Use

• Hospitals and Clinics
• Diagnostic Laboratories
• Research and Academic Institutes
• Others

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/